Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive £86.6m over the next five years to fund 15 research themes.

BRCs bring together academics and clinicians to translate scientific breakthroughs into potential new treatments, diagnostics and medical technologies that benefit NHS patients. The Oxford BRC – whose research covers a range of health themes including cancer, genomics, vaccines, diabetes, cardiovascular medicine and microbiology – was one of the five original BRCs created in 2007 and has just celebrated its 15th anniversary.

Cancer-related research features in 9 out of 15 of the Oxford BRC’s research themes, including a dedicated Cancer Theme led by Professors Xin Lu (Ludwig Institute for Cancer Research) and Tim Elliott (Nuffield Department of Medicine) aiming to improve patient outcomes through early detection and earlier intervention with immunotherapy.

In total, the NIHR has awarded nearly £800 million to 20 Biomedical Research Centres across England, following an open and competitive process judged by international experts and members of the public.

Read the full story on the Oxford BRC website.

Similar Stories

OCION: In conversation with Alfred Zippelius

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Alfred Zippelius to discuss his research.